Filing Flows

Filing Flows › Companies › ClearPoint Neuro › Cash flow

ClearPoint Neuro cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$20.2M in Q3 2026 · −$33.2M over twelve months

Operating cash flow−$20.1M
Capital spending−$137K
Free cash flow−$20.2M
Cash conversion cycle203 days

Analysis

In Q3 2026, ClearPoint Neuro generated −$20.1M of operating cash flow and spent $137K on capital projects, leaving free cash flow of −$20.2M. That is $16.9M less than in Q3 2025 (−$3.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$32.1M; the largest uses were operating cash flow ($32.1M), taxes on employees’ shares ($2.2M), capital spending ($1.0M); besides operations, cash came from other financing ($22.8M), net borrowing (+) / repaid (−) ($19.4M); the cash balance rose by $8.7M.

Operating cash flow was −$5.1M against net income of −$7.5M. The largest differences: stock-based pay +$1.9M, payables −$1.0M, receivables +$940K.

Its cash conversion cycle was 203 days (receivables 63 + inventory 170 − payables 29).

Free cash flow

ClearPoint Neuro: free cash flow by quarterClearPoint Neuro: free cash flow by quarter−$1.5MQ4 2024−$6.4MQ1 2025−$2.6MQ2 2025−$3.3MQ3 2025−$12.1MQ4 2025−$8.6MQ1 2026−$7.2MQ2 2026−$20.2MQ3 2026
Operating cash flow less capital spending.
ClearPoint Neuro: operating cash flow against capital spendingClearPoint Neuro: operating cash flow against capital spendingOperating cash flowCapital spending−$1.2M$263KQ4 2024−$6.2M$183KQ1 2025−$2.6M$91KQ2 2025−$3.1M$199KQ3 2025−$12.1M$49KQ4 2025−$8.0M$645KQ1 2026−$7.0M$214KQ2 2026−$20.1M$137KQ3 2026
Latest (Q3 2026): Operating cash flow −$20.1M, Capital spending $137K.

Capital allocation, year by year

ClearPoint Neuro: where the cash came from (up) and went (down), by fiscal yearClearPoint Neuro: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$12.7MFY2021: Shares issued $47.0MFY2021: Capital spending −$168K$47.0MFY2021FY2022: Operating cash flow −$16.2MFY2022: Shares issued $477KFY2022: Capital spending −$253K$477KFY2022FY2023: Operating cash flow −$13.7MFY2023: Capital spending −$717KFY2023FY2024: Operating cash flow −$8.9MFY2024: Net borrowing −$10.0MFY2024: Shares issued $16.2MFY2024: Capital spending −$275K$16.2MFY2024FY2025: Operating cash flow −$23.9MFY2025: Net borrowing $48.1MFY2025: Shares issued $3.4MFY2025: Capital spending −$522K$51.5MFY2025
Over these 5 years operating cash flow totalled −$75.4M; the largest uses were operating cash flow ($75.4M) and net borrowing ($10.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$46.2M
Debt$50.8M
Net debt$4.7M
Cash runway17 months

ClearPoint Neuro is burning cash: its operations consume cash, a free cash flow of −$33.2M a year at the current rate against $46.2M of cash and investments: a runway of about 17 months before any new financing.

Where the cash came from and went

ClearPoint Neuro: sources (+) and uses (−) of cash, Q3 2026ClearPoint Neuro: sources (+) and uses (−) of cash, Q3 2026Other financing$22.0MOperating cash flow−$20.1MCash drawn (+) / kept (−)−$16.8MNot reconciled$15.0MCapital spending−$137KShares issued$51K
ClearPoint Neuro: sources (+) and uses (−) of cash, TTM to Q3 2026ClearPoint Neuro: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$32.1MOther financing$22.8MNet borrowing (+) / repaid (−)$19.4MCash drawn (+) / kept (−)−$8.7MTaxes on employees’ shares−$2.2MOther investing$1.1MCapital spending−$1.0MShares issued$732KNot reconciled−$25K

From profit to cash

ClearPoint Neuro: net income to operating cash flow, Q3 2026ClearPoint Neuro: net income to operating cash flow, Q3 2026Net income−$7.5MDepreciation & amortization$103KStock-based pay$1.9MDeferred taxes−$16KReceivables$940KInventory−$750KPayables−$1.0MDeferred revenue−$375KPrepaid and other assets−$382KOperating cash flow−$5.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20266317029203
Q2 20267119049212
Q1 20265617437194
Q4 20254717223195
Q3 20254318232193
Q2 20253916034165
Q1 20254418034190
Q4 20245121335229

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$20.1M−$137K—$51K−$16.8M−$20.2M
Q2 2026−$7.0M−$214K—$455K$6.2M−$7.2M
Q1 2026−$8.0M−$645K—$148K$10.5M−$8.6M
Q4 2025−$12.1M−$49K$19.4M$78K−$8.6M−$12.1M
Q3 2025−$3.1M−$199K——$3.3M−$3.3M
Q2 2025−$2.6M−$91K—$3.3M−$29.3M−$2.6M
Q1 2025−$6.2M−$183K—$21K$7.7M−$6.4M
Q4 2024−$1.2M−$263K—−$34K$1.5M−$1.5M

ClearPoint Neuro: income statement and cash flow

ClearPoint Neuro, Q3 2026: revenue $12.1M (+36% year over year), operating margin -52.4%. The chart follows the revenue to costs, profit and cash.

ClearPoint Neuro: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.